These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 3867790)

  • 1. Silicon metabolism: the basic facts in renal failure.
    Berlyne G; Dudek E; Adler AJ; Rubin JE; Seidman M
    Kidney Int Suppl; 1985 Dec; 17():S175-7. PubMed ID: 3867790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silicon metabolism. II. Renal handling in chronic renal failure patients.
    Adler AJ; Berlyne GM
    Nephron; 1986; 44(1):36-9. PubMed ID: 3748249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accumulation of vitamin E metabolites in the blood of renal failure patients.
    Galli F; Floridi AG; Floridi A; Buoncristiani U
    Clin Nutr; 2004 Apr; 23(2):205-12. PubMed ID: 15030960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Citrate kinetics in patients receiving long-term hemodialysis therapy.
    Bauer E; Derfler K; Joukhadar C; Druml W
    Am J Kidney Dis; 2005 Nov; 46(5):903-7. PubMed ID: 16253731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates.
    Elsharkawy MM; Youssef AM; Zayoon MY
    Hemodial Int; 2006 Oct; 10 Suppl 2():S16-23. PubMed ID: 17022745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible cobalt toxicity in maintenance hemodialysis patients after treatment with cobaltous chloride: a study of blood and tissue cobalt concentrations in normal subjects and patients with terminal and renal failure.
    Curtis JR; Goode GC; Herrington J; Urdaneta LE
    Clin Nephrol; 1976 Feb; 5(2):61-5. PubMed ID: 1253458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secreted platelet proteins with antiheparin and mitogenic activities in chronic renal failure.
    Guzzo J; Niewiarowski S; Musial J; Bastl C; Grossman RA; Rao AK; Berman I; Paul D
    J Lab Clin Med; 1980 Jul; 96(1):102-13. PubMed ID: 6446588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperhomocysteinemia and protein damage in chronic renal failure and kidney transplant pediatric patients--Italian initiative on uremic hyperhomocysteinemia (IIUH).
    Perna AF; Ingrosso D; Molino D; Galletti P; Montini G; Zacchello G; Bellantuono R; Caringella A; Fede C; Chimenz R; De Santo NG
    J Nephrol; 2003; 16(4):516-21. PubMed ID: 14696753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
    Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
    Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of renal failure and hemodialysis on serum and urine myoglobin.
    Hart PM; Feinfeld DA; Briscoe AM; Nurse HM; Hotchkiss JL; Thomson GE
    Clin Nephrol; 1982 Sep; 18(3):141-3. PubMed ID: 7140026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative assessment of carnitine loss during haemodialysis and haemofiltration.
    Rumpf KW; Leschke M; Eisenhauer T; Becker K; Köthe U; Scheler F
    Proc Eur Dial Transplant Assoc; 1983; 19():298-301. PubMed ID: 6878244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium exposure and removal in chronic hemodialysis patients.
    Sigrist M; McIntyre CW
    J Ren Nutr; 2006 Jan; 16(1):41-6. PubMed ID: 16414440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced glycation end products in renal failure.
    Thornalley PJ
    J Ren Nutr; 2006 Jul; 16(3):178-84. PubMed ID: 16825015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodialysis of mefenamic acid in uremic patients.
    Wang LH; Lee CS; Marbury TC
    Am J Hosp Pharm; 1980 Jul; 37(7):956-8. PubMed ID: 7395889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxalic Acid as a uremic toxin.
    Mydlík M; Derzsiová K
    J Ren Nutr; 2008 Jan; 18(1):33-9. PubMed ID: 18089441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma, red cell and cerebrospinal fluid concentrations of mannitol and sorbital in patients with severe chronic renal failure.
    Pitkänen E; Bardy A; Pasternack A; Servo C
    Ann Clin Res; 1976 Dec; 8(6):368-73. PubMed ID: 188373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silicon metabolism. I. Some aspects of renal silicon handling in normal man.
    Berlyne GM; Adler AJ; Ferran N; Bennett S; Holt J
    Nephron; 1986; 43(1):5-9. PubMed ID: 3703066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profound mishandling of protein glycation degradation products in uremia and dialysis.
    Agalou S; Ahmed N; Babaei-Jadidi R; Dawnay A; Thornalley PJ
    J Am Soc Nephrol; 2005 May; 16(5):1471-85. PubMed ID: 15800128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.